Stano-K 50 - Kassel Pharma

First introduced to the U.S. pharmaceutical market in 1962, Stanozolol was marketed as Winstrol and produced by Winthrop Laboratories. It became notable for its oral bioavailability and lack of estrogenic activity. Approved to treat muscle-wasting conditions and bone disorders, it also gained traction in veterinary circles, particularly for equine use. While human use declined due to regulatory tightening, injectable veterinary forms remained in circulation. Today, Stanozolol’s reputation as a non-aromatizing, lean-tissue-preserving compound continues in specific global contexts

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Stano-K 50 by Kassel Pharma, consult with your doctor or healthcare professional.